Australia's Mesoblast will make the leap from drug discovery as Japanese partner JCR Pharmaceutical received approval to begin sales of an off-the-shelf allogeneic, or regenerative, medical product, Temcell, based on Mesoblast technology, the Sydney Morning Herald reports. "Under its agreement with JCR, Mesoblast is entitled to receive a milestone payment on this product regulatory approval, as well as royalties and other payments at pre-defined thresholds of cumulative net sales," Mesoblast said in a release. In April, Mesoblast and U.S.-based Celgene ($CELG) entered into an investment and development deal for cancer and immune-inflammatory related diseases that also covers stem cell product candidates, including right-of-first-refusal for 6 months over the proprietary mesenchymal lineage adult stem cell product candidates from Mesoblast. Report